In the News

Dec 22, 2022

Levine Media Group

Targeting a Novel Checkpoint to Treat Cancer and Autoimmune Conditions

Nov 22, 2022

OncLive

Investigators Look to Translate Positive Results of Eftilagimod Alpha Combination to NSCLC

Nov 21, 2022

In Vivo

The Journey Has Just Begun For LAG-3 Therapeutics

Nov 15, 2022

BioWorld

Immutep’s LAG-3 efti, with pembrolizumab, meets primary endpoint in first-line NSCLC

Nov 03, 2022

SITC

SITC to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting

Media

Immutep Limited (ASX: IMM; NASDAQ: IMMP), 18 Aug 2021 – Bell Direct’s Jessica Amir speaks to Immutep's Executive Director and CEO, Marc Voigt

Immutep Limited (ASX: IMM; NASDAQ: IMMP) 04 May 2021 – CEO and Executive Director Marc Voigt speaks with Share Cafe's Tim McGowen about Immutep’s leading position within the LAG-3 competitive landscape

Finance News Network Interview, 29 Mar 2021, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial

Benzinga Biotech Small Cap Conference with CEO Marc Voigt, Wednesday, 24 March 2021, Immutep Limited (ASX: IMM, NASDAQ:IMMP) – CEO Presentation

Ausbiz Interview with CEO Marc Voigt, 17 March 2021, Immutep Limited (ASX: IMM; NASDAQ:IMMP) – Immutep Collaborates with US-based Merck & Co

Finance News Network Interview, 27 Jan 2021, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt analyses December's breast cancer data, and provides an update on efti's position and outlook